Seizures

Neurology
14
Pipeline Programs
9
Companies
15
Clinical Trials
1 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
1
5
5
Early DiscoveryClinical DevelopmentMarket

On Market (3)

Approved therapies currently available

U
LACOSAMIDEApproved
lacosamide
Unknown Company
oral2024
U
MOTPOLY XRApproved
lacosamide
Unknown Company
oral2023
UP
VIMPATApproved
lacosamide
UCB Pharma
oral2010

Competitive Landscape

9 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
3 programs
1
1
lacosamidePhase 41 trial
Levetiracetam 1 g IV + Lorazepam 2 mg IVPhase 2/31 trial
LacosamideN/A1 trial
Active Trials
NCT01236001Completed192Est. Mar 2012
NCT00465244Withdrawn0Est. May 2010
NCT02409433Terminated3Est. Nov 2015
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
3 programs
2
1
Ezogabine/Retigabine IRPhase 41 trial
RetigabinePhase 31 trial
RetigabinePhase 31 trial
Active Trials
NCT00232596Completed306Est. Jan 2008
NCT00235755Completed539Est. Apr 2008
NCT01721317Terminated6Est. Jun 2013
SK Life Science
SK Life ScienceNJ - Paramus
3 programs
3
CarisbamatePhase 31 trial
RWJ-333369Phase 31 trial
RWJ-333369Phase 31 trial
Active Trials
NCT05219617RecruitingEst. Dec 2028
NCT00697762TerminatedEst. May 2008
NCT00697918CompletedEst. Apr 2009
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
CVL-865Phase 21 trial
Active Trials
NCT04686786Terminated105Est. Dec 2024
Novartis
NovartisBASEL, Switzerland
1 program
1
Investigational new drug, company code: BGG492Phase 21 trial
Active Trials
NCT00887861Completed37Est. Aug 2010
Catalyst Pharmaceuticals
Catalyst PharmaceuticalsCORAL GABLES, FL
1 program
1
BumetanidePhase 11 trial
Active Trials
NCT00830531Completed43Est. Jan 2019
Pfizer
PfizerNEW YORK, NY
1 program
A Safety Study For Prevenar 13 Among Chinese ChildrenN/A1 trial
Active Trials
NCT03656939Completed21,240Est. Jul 2020
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
EpidiolexN/A1 trial
Active Trials
NCT05772429Active Not Recruiting158Est. Jul 2026
E
EisaiChina - Liaoning
1 program
PerampanelN/A1 trial
Active Trials
NCT04202159Completed187Est. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
UCB Pharmalacosamide
Bausch HealthEzogabine/Retigabine IR
SK Life ScienceCarisbamate
SK Life ScienceRWJ-333369
SK Life ScienceRWJ-333369
Bausch HealthRetigabine
Bausch HealthRetigabine
UCB PharmaLevetiracetam 1 g IV + Lorazepam 2 mg IV
AbbVieCVL-865
NovartisInvestigational new drug, company code: BGG492
Catalyst PharmaceuticalsBumetanide
Jazz PharmaceuticalsEpidiolex
EisaiPerampanel
PfizerA Safety Study For Prevenar 13 Among Chinese Children
UCB PharmaLacosamide

Clinical Trials (15)

Total enrollment: 22,816 patients across 15 trials

NCT02409433UCB Pharmalacosamide

Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management

Start: Aug 2014Est. completion: Nov 20153 patients
Phase 4Terminated
NCT01721317Bausch HealthEzogabine/Retigabine IR

Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures

Start: Dec 2012Est. completion: Jun 20136 patients
Phase 4Terminated
NCT05219617SK Life ScienceCarisbamate

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Start: Apr 2022Est. completion: Dec 2028
Phase 3Recruiting
NCT00697918SK Life ScienceRWJ-333369

Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures

Start: Mar 2008Est. completion: Apr 2009
Phase 3Completed
NCT00697762SK Life ScienceRWJ-333369

Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures

Start: Oct 2007Est. completion: May 2008
Phase 3Terminated
NCT00235755Bausch HealthRetigabine

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

Start: Dec 2005Est. completion: Apr 2008539 patients
Phase 3Completed
NCT00232596Bausch HealthRetigabine

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

Start: Sep 2005Est. completion: Jan 2008306 patients
Phase 3Completed
NCT00465244UCB PharmaLevetiracetam 1 g IV + Lorazepam 2 mg IV

Seizure Therapy With Intravenous Levetiracetam and Lorazepam

Start: Jan 2008Est. completion: May 20100
Phase 2/3Withdrawn
NCT04686786AbbVieCVL-865

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Start: Dec 2020Est. completion: Dec 2024105 patients
Phase 2Terminated
NCT00887861NovartisInvestigational new drug, company code: BGG492

Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery

Start: Mar 2009Est. completion: Aug 201037 patients
Phase 2Completed
NCT00830531Catalyst PharmaceuticalsBumetanide

Pilot Study of Bumetanide for Newborn Seizures

Start: Jan 2010Est. completion: Jan 201943 patients
Phase 1Completed
NCT05772429Jazz PharmaceuticalsEpidiolex

Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting

Start: Apr 2023Est. completion: Jul 2026158 patients
N/AActive Not Recruiting
NCT04202159EisaiPerampanel

A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures

Start: Jan 2020Est. completion: Mar 2023187 patients
N/ACompleted
NCT03656939PfizerA Safety Study For Prevenar 13 Among Chinese Children

A Safety Study For Prevenar 13 Among Chinese Children

Start: Aug 2018Est. completion: Jul 202021,240 patients
N/ACompleted
NCT01236001UCB PharmaLacosamide

Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older

Start: Sep 2010Est. completion: Mar 2012192 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
7h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
7h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
7h ago

Director of Finance

CoMind
London, UK
7h ago

Electronics Engineering Manager

CoMind
London, UK
7h ago

Director of Information Technology

Zavation Medical Products
7h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 22,816 patients
9 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)